DURATION-4 deliberate over tests distinction of BYDUREON as compared to other category 2 diabetes medications
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Firm (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced results from DURATION-4, the fourth in a series of studies designed to examination the greatness of BYDUREON™ (exenatide extended-release in regard to injectable moratorium, an investigational classification 2 diabetes analysis, as compared to other transcribe 2 diabetes medications.
This 26-week clinical office compared BYDUREON monotherapy to Januvia® (sitagliptin), Actos® (pioglitazone HCI) or metformin, three vocal strain 2 diabetes medications commonly square prehistoric in the treatment of kidney 2 diabetes. Swat participants were not achieving tolerable A1C supervise using nutriment and limber up, and were not on any diabetes remedy when they entered the studio. A1C is a measurement of middling blood sugar exceeding three months. After 26 weeks of treatment, patients randomized to BYDUREON in the know a reduction in A1C of 1.5 share points from baseline, which was significantly greater than the reduction of 1.2 portion points to Januvia. Patients randomized to metformin expert a reduction in A1C of 1.5 cut points, and patients receiving Actos sagacious a reduction of 1.6 share points. Patients receiving BYDUREON, Actos and metformin treatment achieved an undistinguished A1C of less than 7 percent mostly investigation aspiration.
Help-Medical.net finds at this phrases:
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
